# Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

> **NCT01435044** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 239 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** GS-0938
- **DRUG:** RBV
- **DRUG:** Placebo to match sofosbuvir
- **DRUG:** Placebo to match GS-0938

## Key facts

- **NCT ID:** NCT01435044
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-04
- **Final completion:** 2013-05
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2014-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435044, "Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01435044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*